Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Beigene, Ltd. (ONC)
:ONC
Holding ONC?
Track your performance easily
ONC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$126.97 - $248.16
Previous CloseN/A
VolumeN/A
Average Volume (3M)409.16K
Market Cap
$20.18B
Enterprise Value$22.17B
Total Cash (Recent Filing)$100.49M
Total Debt (Recent Filing)$6.19M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Mar 26, 2025EPS Estimate
-0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.24
Shares Outstanding97,717,560
10 Day Avg. Volume251,395
30 Day Avg. Volume409,162
Standard Deviation0.13
R-Squared0.06
Alpha0.00304
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.48
Price to Cash Flow (P/CF)28.50
P/FCF Ratio74.30
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue6.68
Enterprise Value/Gross Profit10.66
Enterprise Value/Ebitda-29.61
Forecast
1Y Price Target
$257.90Price Target Upside45.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe combination of Sonrotoclax and Brukinsa showed impressive response rates, with therapy being well-tolerated and minimal discontinuation due to adverse effects.
Drug DevelopmentBGNE's CLL trials cover the entire treatment landscape, positioning the company well to capture the full value of the CLL market.
Product PerformanceBrukinsa continues to demonstrate its best-in-class efficacy and safety shortly after becoming the #1 prescribed BTKi in the U.S.
Bears Say
Financial PerformanceThe company's loss from operations was reduced to US$120.3 million from US$134.0 million.
Growth RateThe ~8% QoQ growth rate is lower than prior quarters, where QoQ growth has been typically in the mid-to-high teens.
Market CompetitionDespite progress, competition in the domestic market remains a balancing factor for the company's performance.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ONC FAQ
What was Beigene, Ltd.’s price range in the past 12 months?
Beigene, Ltd. lowest stock price was $126.97 and its highest was $248.16 in the past 12 months.
What is Beigene, Ltd.’s market cap?
Beigene, Ltd.’s market cap is $20.18B.
When is Beigene, Ltd.’s upcoming earnings report date?
Beigene, Ltd.’s upcoming earnings report date is Mar 26, 2025 which is in 71 days.
How were Beigene, Ltd.’s earnings last quarter?
Beigene, Ltd. released its earnings results on Nov 12, 2024. The company reported -$1.15 earnings per share for the quarter, missing the consensus estimate of -$1.114 by -$0.036.
Is Beigene, Ltd. overvalued?
According to Wall Street analysts Beigene, Ltd.’s price is currently Undervalued.
Does Beigene, Ltd. pay dividends?
Beigene, Ltd. does not currently pay dividends.
What is Beigene, Ltd.’s EPS estimate?
Beigene, Ltd.’s EPS estimate is -0.92.
How many shares outstanding does Beigene, Ltd. have?
Beigene, Ltd. has 97,717,560 shares outstanding.
What happened to Beigene, Ltd.’s price movement after its last earnings report?
Beigene, Ltd. reported an EPS of -$1.15 in its last earnings report, missing expectations of -$1.114. Following the earnings report the stock price went down -5.56%.
Which hedge fund is a major shareholder of Beigene, Ltd.?
Currently, no hedge funds are holding shares in ONC
---
BeiGene Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$257.90 (45.95% Upside)
$257.90 (45.95% Upside)
Blogger Sentiment
Bullish
ONC Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 48.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.8B over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.94%
12-Months-Change
Fundamentals
Return on Equity
-23.90%
Trailing 12-Months
Asset Growth
5.54%
Trailing 12-Months
Company Description
Beigene, Ltd.
BeiGene, Ltd.is a biopharmaceutical company. The company primarily focuses on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer.
---
ONC Stock 12 Month Forecast
Average Price Target
$257.90
▲(45.95% Upside)
Technical Analysis
Best Analysts Covering ONC
1 Year
1 Year Success Rate
20/28 ratings generated profit
1 Year Average Return
+26.96%
reiterated a buy rating 28 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +26.96% per trade.
---